deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04019288

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Randomized Phase I/II Study of AVB-S6-500 in Combination With Durvalumab (MEDI4736) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

Sponsor: Aravive Biologics Inc

Conditions Platinum-Resistant Fallopian Tube Carcinoma Platinum-Resistant Ovarian Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Refractory Fallopian Tube Carcinoma Refractory Ovarian Carcinoma Refractory Primary Peritoneal Carcinoma
Interventions Batiraxcept Durvalumab
Updated 21 times since 2019 Last updated: May 22, 2025 Started: Dec 3, 2019 Primary completion: Oct 24, 2024 Completion: Oct 24, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

PI Request

Other Platinum-Resistant Fallopian Tube Carcinoma trials with similar outcome

Browse all Platinum-Resistant Fallopian Tube Carcinoma trials

Listed as NCT04019288, this PHASE1/PHASE2 trial focuses on Platinum-Resistant Fallopian Tube Carcinoma and Platinum-Resistant Ovarian Carcinoma and remains terminated or withdrawn. Sponsored by Aravive Biologics Inc, it has been updated 21 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Jul 2023 · 6 months · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Jan 2024 · 4 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Jul 2025 · 8 months · monthly snapshot~Jul 2025 – present · 14 months · monthly snapshot

Change History

21 versions recorded

  1. Jul 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

    Status: Completed → Terminated

  2. Nov 2024 — Jul 2025 [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

  3. Oct 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 16 earlier versions

  1. Jan 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Sep 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Jul 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jan 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Sep 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jan 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Feb 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  11. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  12. Apr 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  13. Dec 2019 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  14. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Sep 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  16. Aug 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aravive Biologics Inc
  • AstraZeneca
  • M.D. Anderson Cancer Center
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations